Meanwhile, subgroup analysis pooling studies with HER2+ patients [51, 64] revealed that HR+/HER2+ breast cancer were significantly associated with worse treatment responses in the neoadjuvant setting (OR 0.43; 95% CI 0.21–0.88; p=0.02). The gene discussed is ERBB2; the disease is breast carcinoma.